TKT Brings Back Astrue; Legal, Political Focus Suggests New Biotech Model
Executive Summary
Transkaryotic Therapies is bringing back Michael Astrue to head a turnaround effort as the company looks to recover from a recent series of adverse regulatory and judicial decisions
You may also be interested in...
TKT Replagal Decision On New Trial Expected In Four Months
Transkaryotic Therapies will decide this summer after meeting with FDA whether to conduct additional clinical trials with its Fabry disease agent Replagal
TKT Replagal Decision On New Trial Expected In Four Months
Transkaryotic Therapies will decide this summer after meeting with FDA whether to conduct additional clinical trials with its Fabry disease agent Replagal
Fabrazyme Market Could Grow With Dialysis Patients, Women, Children
Genzyme expects the Fabry disease incidence in dialysis patients to nearly double the market for its Fabry therapy Fabrazyme